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Human APOBEC3F is an antiretroviral single-strand
DNA cytosine deaminase, susceptible to degrada-
tion by the HIV-1 protein Vif. In this study the crystal
structure of the HIV Vif binding, catalytically active,
C-terminal domain of APOBEC3F (A3F-CTD) was
determined. The A3F-CTD shares structural motifs
with portions of APOBEC3G-CTD, APOBEC3C, and
APOBEC2. Residues identified to be critical for Vif-
dependent degradation of APOBEC3F all fit within a
predominantly negatively charged contiguous region
on the surface of A3F-CTD. Specific sequence
motifs, previously shown to play a role in Vif suscep-
tibility and virion encapsidation, are conserved
across APOBEC3s and between APOBEC3s and
HIV-1 Vif. In this structure these motifs pack against
each other at intermolecular interfaces, providing
potential insights both into APOBEC3 oligomeriza-
tion and Vif interactions.
INTRODUCTION
Members of the AID/APOBEC family of polynucleotide cytosine
deaminases are robust DNA mutators that not only play diverse
immunologic roles (Biasin et al., 2010; Hamilton et al., 2010), but
are also implicated in genome-wide mutation events with signif-
icant repercussions for fundamental biologic phenomena such
as cancer, epigenetic remodeling, and evolution (Burns et al.,
2013; Conticello, 2012; Guo et al., 2011; Nik-Zainal et al.,
2012; Roberts et al., 2012). All seven members of the human
APOBEC3 subfamily likely participate to varying degrees in
restricting retroviruses, inhibiting mobility of active retroele-
ments, and mediating clearance of foreign DNA (Stenglein
et al., 2010). The mammalian APOBEC3 proteins coordinate
zinc and have been classified into Z1, Z2, and Z3 domains
(LaRue et al., 2009). Each of the human APOBEC3 domains
contains a single Z-signature sequence (LaRue et al., 2009).1042 Structure 21, 1042–1050, June 4, 2013 ª2013 Elsevier Ltd All riAccording to this classification, both APOBEC3F domains are
Z2, as is the single-domain APOBEC3C (A3C), whereas the
APOBEC3G (A3G) N-terminal domain is Z2 and the catalytically
active A3GC-terminal domain is Z1 (Figure S1A available online).
These signature sequences emphasize the evolutionary relation-
ships across the various APOBEC3 proteins with deeper
implications for structure and function (LaRue et al., 2008, 2010).
At least two APOBEC3 proteins, A3G and A3F, are central to
the innate immune response against HIV-1 (Bishop et al., 2004;
Harris et al., 2003; Lecossier et al., 2003; Liddament et al.,
2004; Mangeat et al., 2003; Sheehy et al., 2002; Wiegand
et al., 2004; Zhang et al., 2003; Zheng et al., 2004). Both proteins
are incorporated into budding virions and exert an antiviral effect
upon subsequent infection by introducing point mutations in the
newly reverse transcribed viral ssDNA (Harris et al., 2012). This
deamination-dependent mode of inhibition leads to G-to-A
mutations in the viral genome (Browne et al., 2009; Harris
et al., 2003; Miyagi et al., 2007; Schumacher et al., 2008). A
deamination-independent modemay also suppress viral replica-
tion by directly interfering with reverse transcription (Holmes
et al., 2007a, 2007b; Newman et al., 2005; Strebel, 2005).
During HIV-1 infection, the viral protein virion infectivity factor
(Vif) counters this restriction by forming a complex with CBFb
and the Cul5-E3 ubiquitin ligase that targets APOBEC3 proteins
for polyubiquitination and subsequent proteasomal degradation
(Ja¨ger et al., 2011; Yu et al., 2003; Zhang et al., 2012). Vif may
also counteract the antiviral effect by nondegradation-mediated
mechanisms such as inhibiting the translation of cellular
APOBEC3 mRNA or by inhibiting APOBEC3 encapsidation dur-
ing viral budding (Chiu and Greene, 2008). The structural basis of
Vif-APOBEC3 interaction for proteasomal targeting is still poorly
understood, complicated by Vif being an intrinsically disordered
protein (Auclair et al., 2007; Reingewertz et al., 2009, 2010) that
interacts with more than one APOBEC3 family member (Smith
and Pathak, 2010). Until now, no atomic structure of an
APOBEC3-Vif complex has been determined, thwarting a true
elucidation of this key molecular recognition event.
Recently the crystal and nuclear magnetic resonance (NMR)
structures of three APOBEC family members—APOBEC2, the
C-terminal catalytic domain of APOBEC3G (A3G-CTD), andghts reserved
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substrate single-strand DNA sequence specificity and affinity
(Chen et al., 2008; Holden et al., 2008; Kitamura et al., 2012;
Prochnow et al., 2007; Shandilya et al., 2010). In the analysis of
A3C structure (Kitamura et al., 2012), residues involved in Vif-
dependent degradation were identified, even though unlike
A3F, A3C does not normally restrict HIV (Figure 2 in Zheng
et al., 2004). This analysis highlighted the evolutionarily
conserved regions in the two proteins that are required for Vif-
mediated proteasomal degradation. In conjunction with previous
studies (Albin et al., 2010b; Smith and Pathak, 2010) that identi-
fied other residues in A3F required for Vif-mediated degradation,
the mutational data from (Kitamura et al., 2012) suggest that a
more extensive protein surface is responsible for Vif-dependent
degradation in A3F than in A3C. The absence of an antiretroviral
effect in the case of A3C, coupled with a comparatively smaller
set of Vif-interacting residues (Kitamura et al., 2012) leave
open the possibility that Vif evolved to mitigate the anti-HIV
threat from A3F and A3G (Albin and Harris, 2010), rather than
A3C. In this study, we present the crystal structure A3F-CTD,
an HIV-1 restricting, Vif-binding protein. This structure comple-
ments our previous structure of A3G-CTD (Shandilya et al.,
2010) to provide key insights into APOBEC3-Vif host-pathogen
interaction with potential implications for antiretroviral drug
discovery.
RESULTS
Derivation of an Active A3F Variant for Structural
Studies
The wild-type human APOBEC3F catalytic C-terminal domain
was insoluble and unsuitable for structural studies. In a manner
analogous to engineering a soluble construct of the APOBEC3G
catalytic domain (A3G191384-2K3A) (Chen et al., 2008; Harjes
et al., 2009), a systematic mutagenesis approach was taken to
render the protein soluble and simultaneously maintain key
activities. A series of deletion mutants identified a minimal CTD
construct, A3F185373, which was 5-fold more active than the
full-length protein in an Escherichia coli mutation assay (Figures
1A and 1B). This step was followed by multiple rounds of muta-
genesis yielding a construct with 11 amino acid substitutions,
A3F185373-11X (A3F-CTD), that was amenable to purification
and structural studies (Figure 1). Key intermediate constructs
illustrate enhancement of catalytic activity accompanied by
improvements in solubility as assessed by two-dimensional het-
eronuclear correlation NMR spectroscopy experiments (Figures
1B and 1C). Importantly, A3F185373-11X had a better than wild-
type capacity to restrict Vif-deficient HIV-1 and was still fully sus-
ceptible to Vif-dependent degradation (Figure 1D). Recently
identified mutations conferring resistance to Vif-dependent
proteasomal degradation in human A3C and A3F (Kitamura
et al., 2012) also rendered A3F185373-11X less susceptible to
Vif (Figure 1E).
The Crystal Structure of A3F-CTD
The crystal structure of this HIV-1 restricting, Vif-susceptible
A3F-CTD (A3F185373-11X) construct was determined. After
extensive screening of crystallization conditions (see Supple-
mental Experimental Procedures), diffracting crystals wereStructure 21, 10obtained. The structure was solved in the P1 spacegroup to a
resolution of 2.75 A˚ (Figure 2A; Table 1) with four molecules in
the asymmetric unit. The overall root-mean-square deviation
(rmsd) across the C-a backbone for the four independent mole-
cules is 0.77 A˚, reflecting the conformational plasticity of this
enzyme (Figure 2B).
A3F-CTD has a canonical DNA cytosine deaminase fold,
composed of five b strands, six a helices, and the catalytic
zinc-binding site (Figures 2B and 3A). The zinc atom is coordi-
nated by direct interactions with H249, C280, C283, and indi-
rectly via a water molecule with the catalytic glutamate, E251
(Figure 3B). The zinc-coordinating residue C283 and the catalytic
residue E251 are located on helices a2 and a3 and define the
catalytic pocket.
Intermolecular Interfaces
With four molecules in the asymmetric unit, unique intermolec-
ular interfaces exist within the unit cell. In particular, two exten-
sive interfaces (calculated with PISA [Krissinel and Henrick,
2007]) are observed. The largest interface is a quasi-2-fold sym-
metric/isologous interface formed across identical regions of the
two chains B and D (Figures 2A, 2C, and 2D), and buries a total of
657 A˚2 surface area. On both of these chains, the interface
involves the b1-b2 loop (residues H227–H228), a2-b3 loop region
(residues N266 and N268), a3-b4 loop region (residues L291,
S295, and N298), and the a4-b5 loop (residueG325). The second
interface, a nonsymmetric or heterologous interface, is observed
twice in the asymmetric unit and buries a total of 569 A˚2 (Figures
2A, 2E, and 2F). This heterologous interface, formed both
between chains A and B and between chains C and D (Figures
2A, 2E, and 2F), involves the enzyme active site and a domain-
specific R305-L306 motif (part of the Z2 domain fingerprint) in
chains B and D. Twelve residues contributed by chain B (or D)
form a contiguous surface (A210, R213, S216, H249, W277,
C280, P281, Y307–F309, D311, and A314) comprising one half
of the interface. The complementary half of this interface
is formed of ten surface contiguous residues (E223, V225,
H227–P230, N268, E270, S295, and N298) contributed by chain
A (or C), with H227–H228 inserted nearest the active-site cata-
lytic zinc in the first subunit (chain B [or D]). Interestingly, the
b1-b2 loop region, involved in the formation of both interfaces,
exists in two distinct conformations depending on the interface
(Figure 2B, inset).
A distinguishing feature of double-domain APOBEC3 proteins
is the ability to form catalytically inactive high molecular mass
complexes in cells (Kreisberg et al., 2006). A3F was also shown
to localize to the virion core in this form and a dynamic conver-
sion between high molecular mass and low molecular mass
forms may determine differences in activity (Wang et al., 2007).
In our investigations, the A3F-CTD forms complexes of high
molecular mass as observed by dynamic light scattering (Fig-
ure S2). These complexes do not persist in analytical gel filtration
chromatography and are thus not likely to be stable aggregates
but rather transient occurrences in solution (Figures S2A
and S2B). A variant of A3F-CTD in which the VKHH (225–228)
motif within the b1-b2 loop is replaced with MHND, as in A3G-
CTD, does not form the high molecular mass complexes
(Figure S2), suggesting this region mediates favorable intermo-
lecular interactions.42–1050, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 1043
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Figure 1. Derivation of an Active A3F Variant for Structural Studies
(A) Schematic of the N-terminal deletion and amino acid substitutions rendered on wild-type (WT) A3F to yield the soluble variant A3F185-373-11x.
(B) Relative capacity of GST-A3F185-373 (WT) and indicated derivatives to trigger RifR mutation in E. coli. A3F185-373-5x has C259A, F302K, W310K, Y314A,
and Q315A, 7x is 5x plus Y196D and F363D, 9x is 7x plus K355D and K358D and W310D instead of W310K, and 11x is 9x plus H247G and C248R. Data are
reported as the mean ± SEM of the median mutation frequencies acquired from multiple independent experiments (relative to each experiment’s vector-only
control set to 1).
(C) NMR spectra of 1H, 15N-labeled A3F-CTD 7x (30 mM), 9x (30 mM), and 11x (100 mM). HSQC spectra were recorded at 298 K on a Bruker Avance 700 MHz
instrument.
(D and E) Single-cycle HIV-1 infectivity data. Histogram graphs showing the infectivity of Vif-deficient HIVIIIB produced in the presence of a fixed amount of each
indicated full-length A3F-V5 construct and vector control (V) or increasing amounts of Vif-HA. Each bar represents the mean ± SD of duplicate infections
normalized to the corresponding infectivity of virus produced in the absence of A3F. The 11x used in (D) has F363, whereas the 11x in (E) has the same set of
mutations (D363) as those in the final crystallized construct depicted in (A); however, this change does not affect restriction or Vif sensitivity.
See also Figures S1A and S1B.
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Figure 2. Crystallographic Asymmetric
Unit, Crystallographic Binding, and
Potential Oligomerization Interfaces
(A) The A3F-CTD crystal structure asymmetric unit
comprises four chains, illustrated in identical
colors schematically and in the ribbon represen-
tation. Chains A/B and C/D form the heterologous
interface and chains B/D form the isologous
interface. The active site catalytic zinc atoms are
illustrated as blue spheres.
(B) The A3F-CTD has a canonical cytosine
deaminase fold with five b strands and six a heli-
ces. The conformational plasticity in the b1-b2
loop region is highlighted (inset).
(C) The isologous interface, formedbetweenchains
B (cyan) and D (yellow), is the largest interface in
terms of surface area, burying a total of 657 A˚2.
(D) The isologous interface is splayed open to
show interfacial residues (red/orange), with chains
B and D turned by +90/90, respectively. Res-
idues from the two chains B and D, which are
major contributors to this interface, are labeled.
(E) The heterologous interface formed between
chains A (green) and B (cyan) and identical to the
interface between chains C and D is the second
largest interface in terms of surface area, burying
a total of 569 A˚2.
(F) The heterologous interface splayed open to
show interfacial residues (orange/red), with chain
A turned by +180. Residues from the two chains
A and B that are major contributors to this inter-
face are labeled.
See also Figure S2.
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Members
The fold and structure of A3F-CTD is similar to structures of other
APOBEC family members APOBEC2 (Protein Data Bank [PDB]
ID: 2NYT), A3G-CTD (PDB ID: 2KEM, 3IR2, and 3V4K), and
A3C (PDB ID: 3VM8 and 3VOW) (Harjes et al., 2009; KitamuraStructure 21, 1042–1050, June 4, 2013 ªet al., 2012; Li et al., 2012; Prochnow
et al., 2007; Shandilya et al., 2010) (Fig-
ure 3A). The structural similarity parallels
the sequence identity of 25%, 50%, and
77% with APOBEC2, A3G-CTD, and
A3C, respectively (Figure S1B). Structural
analysis reveals specific differences
among these deaminase family mem-
bers. Two changes are due to deletions/
insertions in the sequence. Specifically,
the loop region between the b2 strand
and a2 helix, although disordered in the
electron density, is five residues shorter
in A3F-CTD compared to A3G-CTD. In
addition, sequence alignment reveals
that the secondary zinc coordination site
observed in the A3G b2-a2-loop crystal
structure (Shandilya et al., 2010), which
bridges two molecules in the asymmetric
unit, does not exist in the A3F-CTD
structure (Figure S1B) nor is this siteconserved across APOBEC3 family members. Another two
distinct structural features make A3F-CTD a hybrid between
the other structures. The A3F b2 strand is extended, as in
APOBEC2 and A3C, but not like the A3G-CTD with a discontin-
uous b2-b20 strand. However, a1 helix in A3F-CTD is in the same
conformation as in A3G-CTD and A3C, whereas a1 helix in2013 Elsevier Ltd All rights reserved 1045
Table 1. Crystallographic Statistics for the A3F185–373-11X
Crystal Structure
Resolution 2.75 A˚
Temperature Cryogenic (180C)
Space group P1
Cell Dimensions
a 50.85 A˚
b 67.04 A˚
c 75.77 A˚
a 110.9
b 94.3
g 108.8
Number of molecules
in AU
4
Completeness 98.2% (98.1%; last shell 2.85–2.75 A˚)
Total reflections 22,096
Unique reflections 22,560 (21,432)
I/s 13.5
Average redundancy 2.0
R merge % 6.3
Rmsd
Bonds 0.003 A˚
Angles 0.765
R factor % 19.34
R free % 23.26
A3F185–373-11X (A3F-CTD): PDB ID 4IOU.
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ure 3A). This helix and the following loop region are structurally
conserved in A3G-CTD and A3C (but not APOBEC2) despite
low sequence similarity, indicating this feature to be a conserved
motif of APOBEC3 proteins.
The SWSPCmotif, spanning residues S276–C280 in A3F-CTD
is acommon feature betweenA3F-CTDandotherAPOBEC3pro-
teins that contain either Z1 or Z2 domains (Figure S1A) (LaRue
et al., 2009), analogous to theSSSPCmotif inAPOBEC2proteins.
These motifs may contribute to substrate specificity, potentially
forming a trough in which the polynucleotide (ssDNA) strand
might be positioned (Furukawa et al., 2009; Harjes et al., 2009).
A second loop region playing a role in substrate recognition lies
between the b4 strand and a4 helix (Carpenter et al., 2010; Con-
ticello, 2008; Kohli et al., 2009;Wanget al., 2010). TheC termini of
b3 and b4 strands are two residues shorter in A3F-CTD and A3G-
CTD compared to APOBEC2. A combination of these structural
and sequence differences is likely responsible for modulating
the differential specificity of these APOBEC proteins.
A highly conserved sequence motif across the various human
APOBEC3s is 305-RLYYFWD-311 in A3F-CTD, which is a part of
the Z2 domain specific fingerprint (LaRue et al., 2009) (Figure 4A).
Sequence alignment also reveals this motif to be strongly
conserved in APOBEC3s across mammalian species infected
by lentiviruses (Figure 4B). Within the motif, residues R305–
Y308 are most strongly conserved, whereas larger sequence
variation is observed in residues F309–D311. Structurally, in
the A3F-CTD crystal, this region participates in the heterologous1046 Structure 21, 1042–1050, June 4, 2013 ª2013 Elsevier Ltd All ribinding interface (307–311) (Figures 2A, 2E, and 2F). Residues
R305 and L306 are not involved in intermolecular interactions
but impart structural integrity to the b4-a4 loop. F309 in A3F-
CTD, as Y128 in A3C, assumes a conformation that places the
aromatic side chain in a structurally conserved position. Simi-
larly, D311 in A3F, as D317 in A3G, also assumes a conserved
conformation. However, the Y308 in the LYYF (306–309) motif
in A3F and A3C is not structurally conserved with Y315 in A3G,
potentially distinguishing the Z1 from Z2 family members.
Thus, this motif may likely regulate complex formation across
APOBEC3 proteins.
In contrast to the conserved motifs, the sequence of the b1-b2
loop region involved in forming both intermolecular interfaces
is not conserved across APOBEC3 family members, with
the exception of APOBE3DE-CTD (Figure 4C). Although the
sequences in this region between family members often include
basic residues, their composition and even length varies exten-
sively. Thus this region, which bridges key crystal interfaces,
may serve as an A3F-specific oligomerization determinant.
DISCUSSION
In this study we present a high-resolution crystal structure of the
A3F catalytic domain, elucidating an HIV1 Vif-binding surface,
among all APOBEC3s that exert a demonstrable anti-HIV effect
(Albin and Harris, 2010). The majority of A3F-CTD molecular sur-
face is strongly negatively charged (Figures 5A and 5B). Within
this negatively charged surface, previous studies have identified
Vif-binding regions (Figures 5C and 5D) to include separate por-
tions of the a3 helix (E289–H294, magenta) (Smith and Pathak,
2010), a4 helix (E324, cyan) (Albin et al., 2010b), b3 strand
(Y269) alongwith part of the a2 helix and the adjacent loop region
(L255, F258, C259, I262–S264, green) (Kitamura et al., 2012)
(Figures 5C and 5D). The negative surface of these regions
includes portions of the secondary structure: a3-a4 helices/the
b4 strand and the a2-a3 helices/b3 strand (Figures 5G and 5H)
and the negative surface extends into our crystal contact region
within the b1-b2 loop region (Figures 5C and 5D, orange). Most of
this additional negatively charged surface was not probed by the
previousmutational scans of A3C (Figures 5E and 5F, light green)
(Kitamura et al., 2012). In fact only three residues overlap
between the A3C scan and the b1-b2 loop region: A3C are
K85, L108, and N115; the analogous residues in A3F were not
tested and include N268, L291, and N298 (Figures 5E and 5F,
yellow) (Kitamura et al., 2012). However, L291 (a3) was previ-
ously identified as a part of the Vif-binding region (Smith and
Pathak, 2010) (Figures 5C and 5D, underlined in magenta). Over-
all, the large contiguous negatively charged binding surface is
electrostatically complementary to HIV-1 Vif because Vif is an
extremely positively charged, intrinsically disordered protein,
with an isoelectric point of 10.4. The presence of a negatively
charged contiguous surface suggests that the A3F-Vif binding
interface may extend further along this surface.
Packaging of A3F and A3G into budding virions is essential to
permit the antiviral activity of both A3F and A3G (Huthoff and
Malim, 2007; Kao et al., 2003). In our structure of A3F-CTD, the
crystallographic contacts may be potential oligomerization
surfaces (Figure 2) predominantly involving two regions in the
A3F-CTD sequence, the highly conserved 305-RLYYFWD-311,ghts reserved
Figure 3. Structural Comparison of
APOBEC Family Members
(A) Comparison of ribbon representations of
A3F-CTD, A3G-CTD (3V4K), A3C (3VOW), and
APOBEC2 (2NYT) crystal structures (chain A of all).
The b2/ b2-b20 region is circled in red to highlight
similarities across all proteins except A3G-CTD.
The a1 helix region is boxed in green to highlight
similarities across all proteins except APOBEC2.
(B) The catalytic zinc (blue sphere) is coordinated
at the active site by H249, C280, C283 and indi-
rectly via a water molecule (view occluded by zinc
atom) with E251.
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EVVKHHSPVS-232, which includes the b1-b2 loop (Figures 2
and 4). L306, which forms part of the heterologous interface (Fig-
ures 1A, 1E, and 1F), along withW126 in the analogous portion of
A3F-NTD are involved in localizing A3F to the virion core (Han
et al., 2008; Song et al., 2012). Both of these residues are within
the conserved sequence motif, suggesting this region may be
conserved to facilitate encapsidation of both A3F and A3G into
virions. Specific mutations in the region homologous to A3F
305–311 in human A3G (125YFW127 to 125-DY127) drastically
alter the stability of A3G in the presence of HIV-1 Vif, while not
inhibiting the ability of Vif to bind A3G (Gooch and Cullen,
2008). The other less conserved sequence at the interface
including the b1-b2 loop in A3F is not conserved in A3G. In this
heterologous interface H228 packs into the active site of the cor-
responding molecule in the crystallographic asymmetric unit
(Figure 2). Comparing A3G-CTD with a construct where this
loop was swapped with the corresponding sequence fromFigur
with
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Structure 21, 1042–1050, June 4, 2013 ªA3G, dynamic light scattering data
showed the loop swap variant disrupted
oligomer formation (Figure S2C). Thusthe combination of crystal packing and solution scattering impli-
cates this interface as potentially autoregulating the oligomeriza-
tion mechanism for A3F.
Intriguingly, both A3F sequences (305-RLYYFWD-311 and
223-EVVKHHSPVS-232) potentially involved in oligomerization
align closely with sequences within HIV-1 Vif: 108-HLYYF*D-
113 and 23-SLVKHHMYVS-32 (Figures 4A and 4C). BLAST
(Altschul et al., 1997) searches of human and HIV proteins
verified these matches: the first pair matched well for a
short sequence—the A3F sequence to Vif (A3F:305–311/
Vif:108–113; score 18.5 and e-value 395) and the second
query was even significantly stronger matching the A3F
sequence to Vif (A3F:223–232/Vif:23–32; score 19.7 and e-value
0.4). This suggests that perhaps HIV-1 Vif evolved to mimic
portions of A3F. Substitution mutations in the region of Vif,
replacing 111YF112 with AA, reduce viral infectivity by up to
93% (Simon et al., 1999). This region has also been implicated
in Vif oligomerization (Auclair et al., 2007; Yang et al., 2003),e 4. Sequence Conservation of A3F Loops
Regions of HIV-1 Vif
e 305-RLYYFWD-311 motif of the A3F-CTD b4-a4
is conserved across human APOBEC3 protein
ins and reappears in HIV-1 Vif.
quence alignment of the 305-RLYYFWD-311 motif
A3-CTD b4-a4 loop across a wide array of
alian APOBEC3 proteins.
e 223-EVVKHHSPVS-232 motif of the A3F-CTD
loop is conserved in HIV-1 Vif.
2013 Elsevier Ltd All rights reserved 1047
Figure 5. Surface Representation of the
A3F-CTD Structure
(A) Surface representation, colored by electro-
static potential (blue is positive, red is negative:
0.05 to +0.05 kcal/mol [Maestro 9/Schrodinger]).
The negatively charged groove region, electro-
statically favored to bind the positively charged
Vif, is delineated by the dashed line and highlights
the overlap with known Vif-binding regions in (C).
(B) Same representation as in (A), with the surface
rotated +90 (bottom facing out) along the hori-
zontal axis in the image plane.
(C) a3 helix (289–294, magenta; Smith and Pathak,
2010), the a4 (324, cyan; Albin et al., 2010b), b3
strand (Y269) including part of the a2 helix and the
adjacent loop region (L255, F258, C259, I262–
S264, dark green; Kitamura et al., 2012) are known
Vif-binding regions that adjoin the b1-b2 (E223,
H227–P230), b3(N268, E270), a3(L291, S295),
b4(N298), and the a4-b5 (G325) regions (orange)
involved in forming the interface. The a3 (L291)
residue involved in our intermolecular interface as
well as the previously characterized Vif-binding
region (Smith and Pathak, 2010) is underlined in
magenta.
(D) Same coloring and labels as in (C), with the
surface rotated +90 (bottom facing out) along the
horizontal axis in the image plane.
(E) Highlights of the complete mutational scan
(Kitamura et al., 2012) of A3C (light green) pro-
jected onto our A3F-CTD structure. The regions
that were shown to be important for HIV-1 Vif
binding are highlighted as in (C). Yellow highlights
and labels show the three residues that overlap
between our interface and the A3C mutational
scan not tested in A3F by Kitamura et al., 2012;
however, L291 was independently probed (Smith
and Pathak, 2010) and found to be important in
A3F binding to Vif.
(F) Same coloring and labels as in (E), with the
surface rotated +90 (bottom facing out) along the
horizontal axis in the image plane.
(G) Secondary structure of these views labeled for
reference orientation, with the highlights colored
as in (C). The blue sphere is the catalytic zinc.
(H) Same coloring and labels as in (G), with the
structure rotated +90 (bottom facing out) along
the horizontal axis in the image plane.
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Crystal Structure of APOBEC3F Catalytic Domainperhaps suggesting a mechanism underlying regulation of A3F
activity. Thismechanismmay explain the reduced anti-HIV activ-
ity of A3F even with rates of higher virion packaging when
compared to A3G (Holmes et al., 2007b; Song et al., 2012; Zen-
nou and Bieniasz, 2006). While the regions of A3F have not been
directly implicated in HIV-1 Vif binding, the molecular mimicry of
Vif could play a role in modulating oligomerization or another
molecular recognition event.
Targeting the APOBEC3-Vif interaction for therapeutic inter-
vention has been an inspired goal since the discovery of antiviral1048 Structure 21, 1042–1050, June 4, 2013 ª2013 Elsevier Ltd All rights reservedactivity in this class of enzymes. The ad-
vances that we and others have made
on the structural biology of APOBEC
enzymes in the past couple of years pro-vide us with an understanding of the overall architecture of a cat-
alytic domain (Prochnow et al., 2007), determinants for substrate
interaction of the most prominent family member APOBEC3G
(Chen et al., 2008), the modus operandi of a small molecule
inhibitor (Li et al., 2012) and, recently, determinants for degrada-
tion-dependent Vif susceptibility of APOBEC3C (Kitamura et al.,
2012). With this crystal structure of A3F-CTD, we elucidate
Vif susceptibility determinants based on structure and identify
potential oligomerization interfaces that might help elucidate
the antiviral regulatory role of high molecular mass complexes
Structure
Crystal Structure of APOBEC3F Catalytic Domainof active APOBEC3 proteins. This structure provides the scaffold
to elucidate the APOBEC3 polyubiquitination complex and gives
structural insights that will establish APOBEC3F as a structural
target for antiretroviral strategies.
EXPERIMENTAL PROCEDURES
E. coli-Based Deaminase Activity Assays
An E. coli-based RifR mutation assay used previously to measure DNA cyto-
sine deaminase activity (Chen et al., 2008; Harjes et al., 2009; Harris et al.,
2002) was used to determine the intrinsic deaminase activity of A3F variants
as outlined in the Supplemental Experimental Procedures.
Nuclear Magnetic Resonance HSQC Spectra
The experimental methods have been reported previously (Chen et al., 2008).
HIV-1 Infectivity Assays
Single-cycle infectivity and Vif susceptibility were determined as previously
described (Albin et al., 2010a) and outlined in the Supplemental Experimental
Procedures.
Expression, Crystallization, and Structural Data Analysis
Samples for crystallographic and biophysical characterization (gel filtration
and dynamic light scattering) were prepared and analyzed as described in
the Supplemental Experimental Procedures.
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